Investigating the relationship between interleukin‐6 serum levels and outcome in acute ischemic CVA

INTRODUCTION: Interleukin‐6 (IL‐6) is among the inflammatory mediators exhibiting elevated levels in ischemic stroke (IS) patients. The present study set out to evaluate the relationship between serum levels of interleukin‐6 with long‐term and at‐hospital outcomes of acute ischemic stroke in patients hospitalized at Imam Khomeini Hospital, Urmia, Iran, from 2017 to 2018. METHOD AND MATERIALS: This cross‐sectional descriptive study enrolled 29 and 31 acute stroke patients for long‐term and at‐hospital observation, respectively. Evaluation of stroke severity was performed using the National Institute of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) on days 1, 5, and 90. Serum IL‐6 level was measured via enzyme‐linked immunosorbent assay (ELISA) on days one and five. RESULTS: In the present cohort study, the following population were enrolled: for long‐term evaluation, 11 (38%) men and 18 (63%) women with a mean age of 64.5 ± 14.9 years, and for at‐hospital evaluation: 11 (37.5%) men and 20 (64.5%) with a mean age of 65.25 ± 14.37 years. A significant positive correlation was observed between IL‐6 levels with NIHSS and mRS scores of the patients from time of admission until the end of the follow‐up period (long‐term: p < .001; at‐hospital: 0.022). CONCLUSION: The evidence from the present study suggests that IL‐6 contributes to the determination of the severity of ischemic strokes and may be useful in predicting prognosis. However, larger scale studies are required to further establish these finds.